NIOX Group (LON:NIOX) Insider Sarah Duncan Sells 164,612 Shares of Stock

NIOX Group Plc (LON:NIOX) insider Sarah Duncan sold 164,612 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of GBX 56, for a total value of £92,182.72.

NIOX Group Price Performance

NIOX Group stock opened at GBX 57.40 on Friday. NIOX Group Plc has a 52 week low of GBX 53.84 and a 52 week high of GBX 77.60. The business has a 50-day simple moving average of GBX 60.68 and a 200 day simple moving average of GBX 66.40. The company has a quick ratio of 1.94, a current ratio of 3.81 and a debt-to-equity ratio of 1.36. The stock has a market cap of £239.97 million, a price-to-earnings ratio of 35.00 and a beta of 0.92.

NIOX Group (LON:NIOX) last posted its earnings results on Tuesday, March 24th. The company reported GBX 4.03 EPS for the quarter. NIOX Group had a return on equity of 10.14% and a net margin of 14.37%. On average, research analysts forecast that NIOX Group Plc will post 1.1658256 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft reduced their target price on NIOX Group from GBX 90 to GBX 86 and set a “buy” rating for the company in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, NIOX Group currently has a consensus rating of “Buy” and an average target price of GBX 86.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.